Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
Press Releases
IMPACT Therapeutics  
January 17, 2025

Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer

SHANGHAI, Jan. 16, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce

avatar profile Olean Times Herald

Olean Times Herald


Local & Social